Treatment of chlamydial eye infections

International Ophthalmology Clinics

Volumn 44, Issue 3, 2004, Pages 135-146

  Kalayoglu, Murat V ^a   Pavan Langston, Deborah ^a   Miller, Joan W ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANSAMYCIN DERIVATIVE; AZITHROMYCIN; BACTERIAL VACCINE; CHLAMYDIA TRACHOMATIS VACCINE; CHLAMYDIA VACCINE; CIPROFLOXACIN; CLARITHROMYCIN; DIHYDROFOLATE REDUCTASE INHIBITOR; DOXYCYCLINE; ERYTHROMYCIN; GARENOXACIN; LEVOFLOXACIN; MACROLIDE; NEW DRUG; OFLOXACIN; OUTER MEMBRANE PROTEIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT VACCINE; RIFALAZIL; RIFAMYCIN DERIVATIVE; STEROID; SUBUNIT VACCINE; SULFONAMIDE; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; BACTERIAL GENE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG FORMULATION; DRUG PENETRATION; EYE INFECTION; GASTROINTESTINAL SYMPTOM; GENETIC ENGINEERING; HERPES; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TRACHOMA; VIRUS REACTIVATION;

ANTI-BACTERIAL AGENTS; CHLAMYDIA INFECTIONS; EYE INFECTIONS, BACTERIAL; HUMANS;

EID: 3242740004     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-200404430-00013     Document Type: Review

References (43)

1. Kalayoglu MV, Byrne GI. Chlamydia. In: Dworkin M, ed. Prokaryotes. New York, NY: Springer-Verlag; 2001:e1-e16.
2. Stamm WE. Chlamydia trachomatis infections: progress and problems. J Infect Dis. 1999;179(suppl 2):S380-S383.
3. Fraser-Hurt N, Mabey D. Trachoma. Clin Evid. 2002;7:605-615.
4. Kalayoglu MV, Hahn DL, Byrne GI. Chlamydia infection and pneumonia. In: Paradise L, Friedman H, eds. Opportunistic Intracellular Bacteria and Immunity. New York, NY: Plenum Press; 1999.
5. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA. 2002;288:2724-2731.
6. Beatty WL, Morrison RP, Byrne GI. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev. 1994;58:686-699.
7. Kalayoglu MV. Ocular chlamydial infections: pathogenesis and emerging treatment strategies. Curr Drug Targets Infect Disord. 2002;2:85-91.
8. Hughes RA, Keat AC. Reiter's syndrome and reactive arthritis: a current view. Semin Arthritis Rheum. 1994;24:190-210.
9. Grayston J, Kuo C, Campbell L, et al. Chlamydia pneumoniae sp. nov. for chlamydia sp. strain TWAR. Int J Syst Bacterial. 1989;39:88-90.
10. Lietman T, Brooks D, Moncada J, et al. Chronic follicular conjunctivitis associated with chlamydia psittaci or chlamydia pneumoniae. Clin Infect Dis. 1998;26:1335-1340.
11. Huhtinen M, Laasila K, Granfors K, et al. Infectious background of patients with a history of acute anterior uveitis. Ann Rheum Dis. 2002;61:1012-1016.
12. Huhtinen M, Puolakkainen M, Laasila K, et al. Chlamydial antibodies in patients with previous acute anterior uveitis. Invest Ophthalmol Vis Sci. 2001;42:1816-1819.
13. Numazaki K, Chiba S, Aoki K, et al. Detection of serum antibodies to chlamydia pneumoniae in patients with endogenous uveitis and acute conjunctivitis. Clin Infect Dis. 1997;25:928-929.
14. Sundelof B, Gnarpe H, Gnarpe J. An unusual manifestation of chlamydia pneumoniae infection: meningitis, hepatitis, iritis and atypical erythema nodosum. Scand J Infect Dis. 1993;25:259-261.
15. Reilly CD, Jumper JM, Reed JB. Branch retinal vein occlusions are associated with serologic evidence of Chlamydia pneumoniae infection. Available at: http://www.arvo.org ed.
16. Kalayoglu MV, Galvan C, Mahdi OS, et al. Association between Chlamydia pneumoniae infection and age-related macular degeneration. Arch Ophthalmol. 2003;121:478-482.
17. Weger M, Haas A, Stanger O, et al. Chlamydia pneumoniae seropositivity and the risk of nonarteritic ischemic optic neuropathy. Ophthalmology. 2002;109:749-752.
18. Hammerschlag MR, Gelling M, Roblin PM, et al. Treatment of neonatal chlamydial conjunctivitis with azithromycin. Pediatr Infect Dis J. 1998;17:1049-1050.
19. Beem MO, Saxon E, Tipple MA. Treatment of chlamydial pneumonia of infancy. Pediatrics. 1979;63:198-203.
20. Stenberg K, Mardh PA. Treatment of concomitant eye and genital chlamydial infection with erythromycin and roxithromycin. Acta Ophthalmol (Copenh). 1993;71:332-335.
21. Viswalingam ND, Darougar S, Yearsley P. Oral doxycycline in the treatment of adult chlamydial ophthalmia. Br J Ophthalmol. 1986;70:301-304.
22. Fraser-Hurt N, Bailey RL, Cousens S, et al. Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bull World Health Organ. 2001;79:632-640.
23. Schachter J, West SK, Mabey D, et al. Azithromycin in control of trachoma. Lancet. 1999;354:630-635.
24. Chirgwin K, Roblin PM, Hammerschlag MR. In vitro susceptibilities of chlamydia pneumoniae (chlamydia sp. strain TWAR). Antimicrob Agents Chemother. 1989;33:1634-1635.
25. Mabey D, Fraser-Hurt N. Antibiotics for trachoma. Cochrane Database Syst Rev 2002;1.
26. Walker RC, Wright AJ. The fluoroquinolones. Mayo Clin Proc 1991;66:1249-1259.
27. Miyashita N, Fukano H, Yoshida K, et al. In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species. J Infect Chemother. 2002;8:115-117.
28. Hammerschlag MR, Roblin PM. Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrob Agents Chemother. 2000;44:1409.
29. Lipsky BA, Tack KJ, Kuo CC, et al. Ofloxacin treatment of chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. Am J Med. 1990;89:722-724.
30. Morrissey I, Salman H, Bakker S, et al. Serial passage of chlamydia spp. in sub-inhibitory fluoroquinolone concentrations. J Antimicrob Chemother. 2002;49:757-761.
31. Vesely JJ, Pien FD, Pien BC. Rifampin, a useful drug for nonmycobacterial infections. Pharmacotherapy. 1998;18:345-357.
32. Darougar S, Jones BR, Viswalingam N, et al. Family-based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. Br J Ophthalmol 1980;64:291-295.
33. Bailey RL, Arullendran P, Whittle HC, et al. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet. 1993;342:453-456.
34. Kaukoranta-Tolvanen SS, Teppo AM, Laitinen K, et al. Growth of chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathog. 1996;21:215-221.
35. Gieffers J, Fullgraf H, Jahn J, et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation. 2001;103:351-356.
36. Kalayoglu MV, Indrawati X, Morrison RP, et al. Chlamydial virulence determinants in atherogenesis: the role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions. J Infect Dis. 2000;181(suppl 3):S483-S489.
37. Koonin EV, Makarova KS, Aravind L. Horizontal gene transfer in prokaryotes: quantification and classification. Annu Rev Microbiol. 2001;55:709-742.
38. Samra Z, Rosenberg S, Soffer Y, et al. In vitro susceptibility of recent clinical isolates of chlamydia trachomatis to macrolides and tetracyclines. Diagn Microbiol Infect Dis. 2001;39:177-179.
39. Somani J, Bhullar VB, Workowski KA, et al. Multiple drug-resistant chlamydia trachomatis associated with clinical treatment failure. J Infect Dis. 2000;181:1421-1427.
40. Rothstein DM, Hartman AD, Cynamon MH, et al. Development potential of rifalazil. Expert Opin Investig Drugs. 2003;12:255-271.
41. Donati M, Pollini GM, Sparacino M, et al. Comparative in vitro activity of garenoxacin against chlamydia spp. J Antimicrob Chemother. 2002;50:407-410.
42. Igietseme JU, Black CM, Caldwell HD. Chlamydia vaccines: strategies and status. Bio Drugs. 2002;16:19-35.
43. Stephens RS, Lammel CJ. Chlamydia outer membrane protein discovery using genomics. Curr Opin Microbiol. 2001;4:16-20.